Archives
MK-1775: Wee1 Kinase Inhibitor Workflows
2026-09-08
Use MK-1775 to connect Wee1 inhibition with checkpoint biology, chemotherapy sensitization, and cell-fate measurement. This workflow separates growth arrest from cell death so responses in p53-deficient models are interpreted rather than overcalled.
5-Methyl-CTP for Robust mRNA Workflows
2026-09-07
Learn how 5-Methyl-CTP can be integrated into in vitro transcription workflows to screen for stronger RNA integrity and translation performance. A lactating-cow H5N1 mRNA vaccine study provides a practical translational benchmark while highlighting why reagent-level optimization and product-level efficacy must remain distinct.
SCH772984: ERK1/2 Control Beyond MAPK Inhibition
2026-09-07
A translational framework for using SCH772984 to connect ERK1/2 signaling, oncogenic driver context, ferroptosis, and radioresistance research.
Relative and Fractional Viability in Cancer Drug Testing
2026-09-05
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these measurements capture overlapping but nonidentical components of anticancer response. The framework supports time-resolved experimental designs that separate proliferative arrest from cell killing and reduce ambiguity in in vitro drug-response interpretation.
LEE011 succinate: CDK Inhibitor Workflow
2026-09-05
Build more reproducible CDK4/6 experiments with LEE011 succinate by connecting compound handling, time-resolved cell-cycle assays, and proliferation endpoints. This workflow also shows how a prostate cancer biomarker study can inspire—but not overstate—longitudinal assay design in breast cancer research.
Perospirone in Schizophrenia and Kv1.5 Research
2026-09-04
Perospirone supports receptor-focused schizophrenia research while offering a practical route into vascular ion-channel assays. This guide connects its 5-HT2A, D2, and 5-HT1A pharmacology with the newly reported, concentration-dependent Kv inhibition and provides handling, workflow, and troubleshooting strategies.
Trametinib Beyond Cancer: MEK Assay Logic
2026-09-04
Trametinib (GSK1120212) is more than a proliferation inhibitor: it can function as a pathway-causality probe in oncology and endothelial injury models. This article connects MEK–ERK target engagement with apoptosis, hemostasis, and evidence-based assay design.
Sulfo-NHS-LC-Biotin: Practical Protocol Guide
2026-09-03
Sulfo-NHS-LC-Biotin provides water-compatible, irreversible labeling of primary amines on proteins, peptides, and intact-cell surface proteins for downstream avidin or streptavidin capture. It is best suited to stable extracellular or purified-protein workflows and should not be selected for intracellular or reversible biotinylation.
Atorvastatin Research Workflows for Cell Studies
2026-09-02
Atorvastatin gives researchers a practical way to connect cholesterol biosynthesis, small-GTPase signaling, vascular phenotypes, and ferroptosis assays. This workflow-centered guide covers dosing, orthogonal readouts, cross-domain interpretation, and troubleshooting for cardiovascular and hepatocellular carcinoma models.
ARCA Cy3 EGFP mRNA (5-moUTP) Workflow Guide
2026-09-02
Use ARCA Cy3 EGFP mRNA (5-moUTP) to separate mRNA uptake from productive translation in a single mammalian-cell experiment. Its Cy3 label supports direct tracking, while ARCA capping, 5-methoxyuridine modification, and EGFP expression provide complementary readouts for delivery optimization.
Plastid DNA Breaks in Arabidopsis: A DEtail-seq Map
2026-09-02
The reference study applies DNA end tailing and sequencing (DEtail-seq) to define how plastid DNA breaks vary across Arabidopsis development, genetic backgrounds, and environmental conditions. Its findings connect tissue age, ribosomal DNA vulnerability, R-loop accumulation, reactive oxygen species, and DNA repair capacity, while also clarifying how ROS measurements can complement—but not replace—direct organellar DNA-break profiling.
Alfuzosin HCl: From Receptor Signal to BPH Assay
2026-09-01
Explore how Alfuzosin HCl connects α1-adrenergic receptor biology with practical benign prostatic hyperplasia research. This guide develops a decision framework for functional, analytical, and formulation assays rather than repeating conventional clinical or delivery summaries.
Necrostatin-1: RIP1 Signaling in Bone Research
2026-08-31
Necrostatin-1 is a selective RIP1 kinase inhibitor for dissecting necroptosis in bone, inflammatory, and tissue-injury models. This article connects RIP1 pharmacology with a 2025 osteoporosis study and translates its methods into more informative BMSC necroptosis assay decisions.
Chemistry of Silybin: Structure and Research Implications
2026-08-31
Křen and colleagues’ review integrates more than five decades of silybin chemistry, emphasizing the clarification of absolute configuration, separation of silybin diastereomers, and systematic preparation of derivatives. Its practical value lies in showing how chemical identity, stereochemical composition, and functional-group modification should be controlled when interpreting biological studies of milk thistle constituents.
SCH772984 HCl: Reliable ERK1/2 Assays
2026-08-30
Learn how SCH772984 HCl (SKU B5866) can improve the design, interpretation, and reproducibility of ERK-dependent cell viability and proliferation assays. This scenario-based guide connects biochemical potency, solvent compatibility, MAPK pathway controls, and current APEX2–TERT findings without overstating mechanistic conclusions.
607 records 9/41 page Previous Next First page 上5页 678910 下5页 Last page